Solute Carrier Family 7, (Cationic Amino Acid Transporter, Y+ System) Member 11 (SLC7A11) ELISA Kits

SLC7A11 encodes a member of a heteromeric, sodium-independent, anionic amino acid transport system that is highly specific for cysteine and glutamate. Additionally we are shipping SLC7A11 Antibodies (94) and SLC7A11 Proteins (5) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
SLC7A11 23657 Q9UPY5
SLC7A11 310392  
SLC7A11 26570 Q9WTR6
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top SLC7A11 ELISA Kits at antibodies-online.com

Showing 5 out of 14 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Delivery Price Details
Human 4.68 pg/mL 18.75-1200 pg/mL Typical standard curve 96 Tests 15 to 18 Days
$910.56
Details
Rat 0.55 1.56 ng/mL - 100 ng/mL 96 Tests 13 to 16 Days
$800.00
Details
Mouse
  96 Tests 2 to 3 Days
$867.90
Details
Human < 0.059 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests 11 to 18 Days
$902.56
Details
Rat < 0.55 ng/mL 1.56 ng/mL - 100 ng/mL   96 Tests 11 to 18 Days
$966.52
Details

More ELISA Kits for SLC7A11 Interaction Partners

Human Solute Carrier Family 7, (Cationic Amino Acid Transporter, Y+ System) Member 11 (SLC7A11) interaction partners

  1. This study demonstrated that xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.

  2. CD44v overexpression is not involved in cancer stem cell properties but increases xCT expression, which leads to the acquisition of Cisplatin-resistance.

  3. Smoking could induce the expression of xCT (SLC7A11) in oral cancer cells.

  4. Studies indicate that SLC7A11 plays critical roles in glutamine metabolism and regulates the glucose and glutamine dependency of cancer cells.

  5. In a multivariate analysis, high xCT expression and WHO tumor grade but not IDH1 R132H mutation, were significantly associated with epileptic seizures at diagnosis.

  6. Results showed that xCT-mediated glutamate release promotes glioma cell migration via N-methyl-d- aspartate- sensitive glutamate receptor signaling.

  7. the over-expression of SLC7A11, or supplementation with sufficiently cystine, or treatment with N-acetylcysteine significantly decreased P-gp expression and activity. It was suggested that ROS and SLC7A11/cystine were the two relevant factors responsible for the expression and function of P-gp, and that SLC7A11 might be a potential target modulating ADR resistance.

  8. In some breast cancer cells, xCT antiporter expression is upregulated through the antioxidant transcription factor Nrf2 and contributes to their requirement for glucose as a carbon source.

  9. accumulated mutant-p53 protein suppresses the expression of SLC7A11, a component of the cystine/glutamate antiporter, system xC(-), through binding to the master antioxidant transcription factor NRF2.

  10. System xC(-)-mediated TrkA activation therefore presents a promising target for therapeutic intervention in cancer pain treatment.

  11. High expression of cystine-glutamate antiporter SLC7A11 is associated with advanced pathological stages of liver carcinoma. SLC7A11 overexpression is a novel biomarker and a potential unfavorable prognostic factor as well as a potential therapeutic target for liver carcinoma.

  12. the level of antisense SLC7A11 was markedly reduced in epithelial ovarian cancer tissues and cell lines compared with those of normal control; reduction of antisense SLC7A11 level prompted ovarian cancer cell migration mainly by suppressing the expression of SLC7A11

  13. CD44v9 in tumor specimens has potential as a novel indicator for identifying a cisplatin-chemoresistant population among urothelial cancer patients. CD44v8-10 contributes to reactive oxygen species defenses, which are involved in chemoresistance, by promoting the function of xCT, which adjusts the synthesis of glutathione.

  14. Oncogenic PIK3CA alters methionine and cysteine utilization, partly by inhibiting xCT to contribute to the methionine dependency phenotype in human breast cancer cells.

  15. these observations suggest that SLC7A11 may be a vital biomarker for the diagnosis and prognosis in human laryngeal squamous cell carcinoma (LSCC) and targeting SLC7A11 appears to be a potentially significant method for LSCC treatment.

  16. Aberrant neuronal or neuroendocrine system may be involved in the suppressed reproductive performance in xCT deficient male mice.

  17. overexpression of SLC7A11 in the context of glioblastoma multiforme may contribute to tumor progression.

  18. miR-375 served as a tumor suppressor via regulating SLC7A11.

  19. As targets of oncogenes with intrinsic tyrosine kinase activity, STAT3 and STAT5 become constitutively active in hematologic neoplasms and solid tumors, promoting cell proliferation and survival and modulating redox homeostasis via regulation xCT expression. (Review)

  20. Authors found that the xCT expression was increased in peripheral blood monocyte of active tuberculosis. xCT expression in macrophage was induced by Mycobacterium tuberculosis (Mtb) through TLR2/Akt- and p38-dependent signaling pathway.

Mouse (Murine) Solute Carrier Family 7, (Cationic Amino Acid Transporter, Y+ System) Member 11 (SLC7A11) interaction partners

  1. Genetic and pharmacological inhibition of RGS4 resulted in a significant decrease in SLC7A11 (xCT) expression and hypofunction of system xc(-) and reduced glutamatergic function in organotypic brain slice cultures. RGS4 deficit induces dysregulation and dysfunction of system xc(-), which further results in functional deficits of the glutamatergic system and subsequently to schizophrenia-related behavioral phenotypes.

  2. our study reveals Slc7a11 is the key regulator of age-dependent changes in extracellular Eh(Cys/CySS) in primary mouse lung fibroblasts

  3. Lipopolysaccharide (LPS)-injection increased hippocampal xCT expression but did not alter the mainly astroglial localization of the xCT protein. Peripheral and central inflammation (as defined by cytokine levels and morphological activation of microglia) as well as LPS-induced sickness and depressive-like behavior were significantly attenuated in xCT-deficient mice compared with wildtype mice.

  4. In mouse brain parenchyma, xCT is selectively expressed in scattered astrocytes throughout the brain. Especially strong xCT labeling is found in select blood/brain/CSF interface areas: in the leptomeninges, along larger blood vessels, in some circumventricular organs and in tanycytes in parts of the walls of the ventral third ventricle. Study did not find expression of xCT in microglia, oligodendrocytes and neurons.

  5. System xC(-)-mediated TrkA activation therefore presents a promising target for therapeutic intervention in cancer pain treatment.

  6. Authors found that the xCT expression was increased in peripheral blood monocyte of active tuberculosis. xCT expression in macrophage was induced by Mycobacterium tuberculosis (Mtb) through TLR2/Akt- and p38-dependent signaling pathway.

  7. Protein expression of xCT is enhanced in immune cells from an animal model of multiple sclerosis.

  8. Study suggests that mature astrocytes have low expression levels of xCT and that they do not depend on its function to survive. In contrast, oligodendrocytes, which express high levels of xCT, are the most vulnerable cell type of CNS to glutathione depletion upon chronic blockage of xCT or under oxidative glutamate toxicity.

  9. ARF inhibits tumor growth by suppressing the ability of NRF2 to transcriptionally activate its target genes, including SLC7A11, a component of the cystine/glutamate antiporter that regulates reactive oxygen species (ROS)-induced ferroptosis.

  10. Expression of xCT is reduced in astroglia in a genetic mouse model of susceptibility to depressive-like behavior.

  11. Data suggest that glucose starvation of various neoplasm cell lines induces Slc7a11 expression; Slc7a11 overexpression decreases intracellular glutamate, an alternative source of metabolic energy; provision of alpha-ketoglutarate, a key downstream metabolite of glutamate, restores survival in Slc7a11-overexpressing neoplasm cell lines under glucose starvation.

  12. HIF-1alpha plays a role in cerebral ischaemia-reperfusion -induced glutamate excitotoxicity via the long-lasting activation of system xc(-) -dependent glutamate outflow

  13. Results provided important insights into understanding the mechanism associated with xCT deficiency.

  14. Protein expression of xCT was observed throughout the forebrain and amygdala.

  15. Cerebellar astroglia isolated from Atm mutant mice show decreased expression of the cystine/glutamate exchanger subunit xCT, glutathione reductase, and glutathione-S-transferase

  16. IL-1beta increases the level of mRNA encoding xCT in primary cultures of astrocytes isolated from mouse cortex.

  17. Study found that aglycemic neuronal cell death does not result from changes in astrocyte system xc- expression or activity or from impairment of glutamate removal

  18. This study indicated that, under physiological conditions, nonvesicular glutamate release via system xc- mediates aspects of higher brain function related to anxiety and depression, but does not influence sensorimotor function or spatial vision

  19. The study supports a novel role for the Slc7a11 in mediating T cell infiltration into the CNS as well as promoting myelin destruction after immune cell infiltration in experimental autoimmune encephalomyelitis.

  20. This study demonistrated that System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.

SLC7A11 Antigen Profile

Antigen Summary

This gene encodes a member of a heteromeric, sodium-independent, anionic amino acid transport system that is highly specific for cysteine and glutamate. In this system, designated Xc(-), the anionic form of cysteine is transported in exchange for glutamate. This protein has been identified as the predominant mediator of Kaposi sarcoma-associated herpesvirus fusion and entry permissiveness into cells. Also, increased expression of this gene in primary gliomas (compared to normal brain tissue) was associated with increased glutamate secretion via the XCT channels, resulting in neuronal cell death.

Gene names and symbols associated with SLC7A11

  • solute carrier family 7 member 11 (SLC7A11) antibody
  • solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 (SLC7A11) antibody
  • solute carrier family 7 member 11 (Slc7a11) antibody
  • solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 (Slc7a11) antibody
  • 9930009M05Rik antibody
  • AI451155 antibody
  • CCBR1 antibody
  • DKFZp468E122 antibody
  • SLC7A11 antibody
  • sut antibody
  • xCT antibody

Protein level used designations for SLC7A11

solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 , cystine/glutamate transporter , solute carrier family 7, member 11 , Cystine/glutamate transporter , cystine/glutamate transporter-like , solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 , amino acid transport system xc- , calcium channel blocker resistance protein CCBR1 , solute carrier family 7 member 11 , solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 , cysteine/glutamate transporter , sodium independent anionic amino acid transport system

GENE ID SPECIES
428731 Gallus gallus
471310 Pan troglodytes
524078 Bos taurus
696516 Macaca mulatta
100027770 Monodelphis domestica
100049683 Sus scrofa
100091177 Ornithorhynchus anatinus
100172659 Pongo abelii
100386974 Callithrix jacchus
100581045 Nomascus leucogenys
23657 Homo sapiens
310392 Rattus norvegicus
483821 Canis lupus familiaris
26570 Mus musculus
Selected quality suppliers for SLC7A11 (SLC7A11) ELISA Kits
Did you look for something else?